Crown Bioscience Increases APAC Capacity with New Facility in Zhongshan, China
27.10.2020 15:00:00 EET | Business Wire | Press release
Crown Bioscience, a JSR Life Sciences company, today announces the opening of a new oncology-focused research facility in Zhongshan, China to satisfy increased customer demand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005098/en/
CrownBio's New Zhongshan, China Facility (Photo: Business Wire)
In addition to the Company’s four facilities across the US and Europe, CrownBio’s existing APAC footprint currently includes three sites located in Beijing, Taicang, and Suzhou, as well as one in Taiwan. Once completed, this new building will add more than 2,000m2 of new vivarium space to support CrownBio’s in vivo oncology platforms, helping satisfy predicted near-term growth.
CrownBio’s world-leading products and services are used by pharmaceutical and biotech customers across APAC, North America, and Europe to accelerate and de-risk their drug discovery programs. With the significant and continued growth of CrownBio’s client base, the Zhongshan facility has been purpose built to meet expanding study needs.
The research and drug development facility features BSL-2 laboratories and will include a state-of-the-art ABSL-2 vivarium. Initial capabilities will focus on expanding cell line-derived xenograft model availability and study throughput, with an increased roster of cutting edge, translational oncology models becoming available. Full operational capacity is expected in early 2021.
“The establishment of our new Zhongshan facility demonstrates our continued commitment to our clients, to provide sustained rapid study initiation combined with robust cost-effectiveness,” said John Gu, chief operating officer at CrownBio. “Through our growth, we can more fully support our clients in their goals of more rapid and efficient cancer drug development”.
A site opening event and ribbon cutting ceremony will take place on October 30th 2020.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
● https://www.jsrlifesciences.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005098/en/
Contact information
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1NCE and Pessl Instruments Connect Smart Farms Worldwide29.7.2026 11:00:00 EEST | Press release
1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, and Pessl Instruments, a global leader in smart agriculture, announce today the roll-out of the METOS by Pessl Instruments weather network solution powered by 1NCE. The smart farming solution provided by Pessl Instruments connects thousands of weather stations and field sensors through a single platform, providing farmers real-time data of precipitation and soil moisture, extreme weather forecasting and crop disease risk in more than 80 countries. The main challenge for the deployment of smart farming solutions is always providing good coverage in rural areas. Thanks to 1NCE’s global connectivity service available in more than 170 countries, Pessl Instruments can now offer its smart farming solution at global scale with a 99.97% service availability. This consolidates Pessl Instruments as a smart farming powerhouse, helping customers make more informed irrigation and fertilizer de
Cognita Reply Named an OpenAI Advanced Partner to Accelerate Enterprise Adoption of Frontier AI29.7.2026 11:00:00 EEST | Press release
Cognita Reply, the Reply Group company specialising in OpenAI technologies, today announced that it has been named an OpenAI Advanced Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729234340/en/ Cognita Reply, the Reply Group company specialising in OpenAI technologies, today announced that it has been named an OpenAI Advanced Partner within the OpenAI Partner Network, to accelerate enterprise adoption of frontier AI The OpenAI Partner Network is a global programme for partners to build, sell and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities and customer relationships, while equipping them with resources, enablement and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. We’re pleased to welcome Cognita Reply as an OpenAI Advanced Partner. The Cognita Reply
T964 Named as Uptime Institute Business Partner to Power Iraq’s Digital Infrastructure29.7.2026 10:02:00 EEST | Press release
Uptime Institute and Tech964 Holding Limited (T964), Iraq’s leading digital infrastructure company, today announced a landmark strategic partnership to accelerate Iraq’s digital transformation. The partnership combines the world’s leading authority in digital infrastructure standards with the company building the critical infrastructure underpinning Iraq’s digital economy. The agreement was signed at the U.S. Chamber of Commerce U.S.-Iraq Business Summit on July 17, 2026, during the official U.S. visit of Iraqi Prime Minister Ali Al-Zaidi, at a historic summit that produced more than 50 agreements valued at over USD $60 billion and marked a powerful new era of economic cooperation between the United States and Iraq. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728066813/en/ T964 named as Uptime Institute Business Partner to power Iraq's digital infrastructure, landmark agreement signed at U.S. Chamber of Commerce U.S.-
PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants29.7.2026 10:00:00 EEST | Press release
PK MED, a French biotechnology company founded by Truffle Capital (founder of Abivax and Carvolix), developing therapeutic micro-implants to address major medical needs, today announces a significant strengthening of its governance. The company is strengthening the structure of its Board of Directors and Scientific Advisory Board to support the upcoming Phase 2 entry of its most advanced drug candidate, ARTHRELIS (treatment of gout flares), and to accelerate the preclinical development of ENGRAFTIS (treatment of poor graft function following bone marrow transplantation). The Board of Directors of PK MED welcomes four key new members: François Romaneix, appointed Chairman of the Board of Directors. Senior Partner at Truffle Capital, former CEO of the French National Authority for Health (HAS), and former Deputy CEO of the Institut Pasteur, he brings his strategic vision for market access and healthcare corporate governance. Isabelle Buckle, PhD, Board Member. With more than three decade
ELFA Vape Aerosols Less Harmful Than Cigarette Smoke: Study29.7.2026 10:00:00 EEST | Press release
Levels of 17 constituents in aerosols from ELFA, a pod system vape by ELFBAR, are undetected or substantially lower than those in cigarette smoke, reveals the latest peer-reviewed study published by iScience, a scientific journal. Aerosols in this study are generated by facilities under standardized laboratory conditions. The tests involve 17 cigarette smoke-related analytes during vaporization of vape liquid from ELFA’s pods in four flavors, including Super Tobacco, Spearmint, Strawberry Ice and Watermelon. Findings indicate that adult smokers completely transitioning to ELFA pod system could reduce, or even eliminate, their exposure to multiple harmful constituents compared with consuming combustible cigarettes. “This study adds to the growing scientific evidence supporting the effective role vaping products play in reducing, or even eliminating, exposure to harmful chemical substances for adult smokers,” said an ELFBAR spokesperson. “Providing adult users with quality cessation alte
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom